OncoMatch/Clinical Trials/NCT07742332
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
Is NCT07742332 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Fumetinib combined platinum-based double chemotherapy and Concurrent Radiochemotherapy for egfr.
Treatment: Fumetinib combined platinum-based double chemotherapy · Concurrent Radiochemotherapy — The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
EGFR sensitive mutation as confirmed by needle biopsy
Disease stage
Required: Stage II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment for NSCLC
The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.
Lab requirements
Blood counts
Other major organs shall function well (liver, kidney, blood system, etc.)
Kidney function
Other major organs shall function well (liver, kidney, blood system, etc.)
Liver function
Other major organs shall function well (liver, kidney, blood system, etc.)
Other major organs shall function well (liver, kidney, blood system, etc.)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07742332 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages